Androgen Receptor in Hormone Receptor-Positive Breast Cancer
| dc.contributor.author | Khan, Ashfia Fatima | |
| dc.contributor.author | Karami, Samaneh | |
| dc.contributor.author | Peidl, Anthony S. | |
| dc.contributor.author | Waiters, Kacie D. | |
| dc.contributor.author | Babajide, Mariam Funmi | |
| dc.contributor.author | Bawa-Khalfe, Tasneem | |
| dc.date.accessioned | 2024-01-10T14:50:15Z | |
| dc.date.available | 2024-01-10T14:50:15Z | |
| dc.date.issued | 2023-12-29 | |
| dc.date.updated | 2024-01-10T14:50:15Z | |
| dc.description.abstract | Breast cancer subtypes expressing hormone receptors (HR+ BCa) have a good prognosis and respond to first-line endocrine therapy (ET). However, the majority of HR+ BCa patients exhibit intrinsic or acquired ET resistance (ET-R) and rapid onset of incurable metastatic BCa. With the failure of conventional ET, limited targeted therapy exists for ET-R HR+ BCa patients. The androgen receptor (AR) in HR-negative BCa subtypes is emerging as an attractive alternative target for therapy. The AR drives Luminal AR (LAR) triple-negative breast cancer progression, and LAR patients consistently exhibit positive clinical benefits with AR antagonists in clinical trials. In contrast, the function of the AR in HR+ BCa is more conflicting. AR in HR+ BCa correlates with a favorable prognosis, and yet, the AR supports the development of ET-R BCa. While AR antagonists were ineffective, ongoing clinical trials with a selective AR modulator have shown promise for HR+ BCa patients. To understand the incongruent actions of ARs in HR+ BCa, the current review discusses how the structure and post-translational modification impact AR function. Additionally, completed and ongoing clinical trials with FDA-approved AR-targeting agents for BCa are presented. Finally, we identify promising investigational small molecules and chimera drugs for future HR+ BCa therapy. | |
| dc.identifier | doi: 10.3390/ijms25010476 | |
| dc.identifier.citation | International Journal of Molecular Sciences 25 (1): 476 (2024) | |
| dc.identifier.uri | https://hdl.handle.net/10657/15839 | |
| dc.title | Androgen Receptor in Hormone Receptor-Positive Breast Cancer |